Gapping up
In reaction to strong earnings/guidance:
- RH +19.1%, MOV +5.7%, SMAR +4.4%, AZO +3.7%, TLYS +1.1% (announces revised Q3 results, affirms Q4 outlook)
Other news:
- MRNS +11.8% (presents ganaxolone data from its Phase 2 clinical trial in pediatric genetic epilepsies)
- CRON +11.2% (confirms discussions concerning a potential investment by Altria Group (MO))
- CLVS +6.4% (positive outcome in European opposition proceeding related to Rubraca)
- PRQR +6.3% (FDA has cleared the Investigational New Drug (IND) application for QR-421a)
- ALLO +4.1% (reports data from Phase 1 Trials of Allogeneic UCART19)
- AZO +3.7% (after closing near highs ahead of earnings tomorrow before the open)
- TGTX +2.5% (provides updated clinical data from Phase I/Ib trial of ublituximab)
- AQN +2.1% (to purchase Enbridge Gas New Brunswick LP, a subsidiary of Enbridge Inc. (ENB), along with its general partner for C$331 mln)
- FATE +1.6% (secures exclusive option from Max Delbrück Center for Molecular Medicine covering novel humanized anti-BCMA CAR constructs for the development of iPSC-derived cell products)
Analyst comments:
- SIFY +7.1% (initiated with Buy rating and $4 tgt at Maxim Group)
- FSLR +1.8% (upgraded to Buy from Hold at Argus)
- VNDA +1.1% (upgraded to Overweight from Neutral at Cantor Fitzgerald)
- HIG +0.7% (upgraded to Buy from Neutral at Janney)